Investor Presentation H1 2023
43
Investor presentation
First six months of 2023
The total branded diabetes market has a global value of DKK
-395 billion annually
DKK
billion
Global diabetes market
DKK
The USA
billion
500
2022/2023 2021/2022 Growth at CER
300
+18%
+15%
199
+33%
200
394
152
400
-17%
109
+49%
-8%
100
74
325
300
37 41
37
15 14
23
0
Total
Insulin
GLP-1
DPP-4i
SGLT-2i
DKK
Outside the USA
+39%
billion
200
-13%
157
300
+11%
103 112
+47%
195
105
-10%
200
173
100
83
-9%
51 54
+51%
-12%
+49%
54
100
66 71
48
32
36 40
46
31
0
Total
Insulin
GLP-1
DPP-4i
SGLT-2i
0
Total
Insulin
GLP-1
Source: Company announcements as of Q1 2023; 2022/2023 data based on Q2 2022 to Q1 2023 and 2021/2022 data based on Q2 2021 to Q1 2022
Note: The segment value is based on reported figures, whilst the market growth is under constant exchange rate (CER). For Novo Nordisk the diabetes growth includes Insulin and GLP-1, excluding 'other Diabetes care'.
DPP-4i
SGLT-2i
Novo NordiskⓇView entire presentation